Literature DB >> 10552990

A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.

R Wise1, J M Andrews, J P Ashby, J Marshall.   

Abstract

A single 400 mg oral dose of gatifloxacin was given to each of nine healthy male volunteers and the concentrations of the drug in plasma, cantharidine-induced inflammatory fluid and urine were measured over the following 24 h. The mean peak concentration in plasma of 4. 1 mg/L was attained at a mean time of 1.8 h post dose. The mean peak concentration in inflammatory fluid was 3.6 mg/L and was attained at a mean time of 4.2 h post dose. The mean plasma elimination half-life of gatifloxacin was 6.8 h and that in inflammatory fluid was 7.2 h. The mean penetration into the inflammatory fluid was 117%. Recovery of drug from urine during the first 24 h post dose was 65% of that administered. Our data suggest that gatifloxacin dosed at 400 mg od should be adequate to treat systemic infections caused by most bacterial species.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552990     DOI: 10.1093/jac/44.5.701

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.

Authors:  R Wise; T Gee; G Marshall; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.

Authors:  M L Cohn; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.

Authors:  Andrej Trampuz; Gerd Laifer; Markus Wenk; Zarko Rajacic; Werner Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Population pharmacokinetic model for gatifloxacin in pediatric patients.

Authors:  Christopher M Rubino; Edmund V Capparelli; John S Bradley; Jeffrey L Blumer; Gregory L Kearns; Michael Reed; Richard F Jacobs; Brenda Cirincione; Dennis M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

5.  Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 6.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 9.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.